What's Happening?
Mortality rates have become a significant concern in the life insurance industry following the COVID-19 pandemic. Despite expectations, death rates have not returned to pre-pandemic levels, with increased deaths from heart disease, diabetes, chronic liver disease, and drug overdoses contributing to excess mortality. Swiss Re, a leading researcher in the field, has released a study suggesting that GLP-1 weight-loss drugs could reduce cumulative all-cause mortality in the U.S. by 6.4% over the next 20 years. Neil Sprackling, Swiss Re's U.S. Life & Health division president, discussed these findings during the LIMRA 2025 Annual Conference.
Why It's Important?
The findings from Swiss Re's study highlight the potential impact of GLP-1 drugs on public health and mortality rates in the U.S. If these drugs can effectively reduce mortality, it could lead to significant changes in healthcare policies and insurance practices. The life insurance industry may need to adjust its models and offerings based on these potential health improvements. Additionally, the broader healthcare system could see shifts in resource allocation and treatment priorities, benefiting both patients and providers.
